Israel - English - Ministry of Health

abic marketing ltd, israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - - primary hypercholesterolemia: ezetimibe teva administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. - homozygous familial hypercholesterolemia (hofh): ezetimibe teva administered with a statin are indicated for use in patients with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis).- homozygous sitosterolemia (phytosterolemia): ezetimibe teva is indicated for use in patients with homozygous familial sitosterolemia

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - atorvastatin - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - atorvastatin - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - atorvastatin - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - atorvastatin - film-coated tablet - 80 milligram(s) - hmg coa reductase inhibitors; atorvastatin

United States - English - NLM (National Library of Medicine)

prasco laboratories - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24) - ezetimibe 10 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - atorvastatin calcium trihydrate - oral tablet - 10mg

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - atorvastatin calcium trihydrate, quantity: 10.341 mg (equivalent: atorvastatin, qty 10 mg); ezetimibe, quantity: 10 mg - tablet, film coated - excipient ingredients: crospovidone; sodium stearylfumarate; lactose; povidone; sodium lauryl sulfate; colloidal anhydrous silica; microcrystalline cellulose; lactose monohydrate; calcium carbonate; hyprolose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - prevention of cardiovascular disease ezetimibe/atorvastatin is indicated in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) taking their maximum tolerated dose of atorvastatin and in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy,primary hypercholesterolaemia ezetimibe/atorvastatin is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia where use of a combination product is appropriate in those patients: ? not appropriately controlled with atorvastatin or ezetimibe alone; or ? already treated with atorvastatin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh) ezetimibe/atorvastatin is indicated in patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).

Ireland - English - HPRA (Health Products Regulatory Authority)

apotex europe b.v. - ezetimibe - tablets - 10 milligram - ezetimibe

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - atorvastatin calcium trihydrate - oral tablet - 20mg